Jim Cramer, the host of CNBC’s “Mad Money,” is known for his energetic and often controversial takes on the stock market.

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

The union members, most of them based in Washington state, turned down a proposal to raise wages by 25% over four years, as ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.8, a high ...

Gartner IT has outperformed the market over the past 15 years by 13.06% on an annualized basis producing an average annual ...

FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

NovaBay shares are trading higher after the company announced it reached a definitive agreement to sell its Avenova assets ...

Today, Benzinga's options scanner spotted 12 options trades for SoFi Techs. This is not a typical pattern. The sentiment ...

VinFast reports a larger-than-expected Q2 loss and missed sales targets, prompting a drop in shares, despite strong EV ...